Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solriamfetol for EDS in OSA (China Phase 3)
CTR20231397Phase 3Completed
- Sponsor
- Axsome Therapeutics, Inc.
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of solriamfetol in obstructive sleep apnea hypopnea syndrome (OSAHS), Excessive Daytime Sleepiness (EDS), sponsored by Axsome Therapeutics, Inc.. Started May 2023; status: completed.
02
Drugs
solriamfetol
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on CTR20231397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231397.